Market Brief

Daily market recaps with key events, stock movements, and global influences

Related Prediction Markets

•

Sources

Story Timeline

29 days ago•Latest version

Eli Lilly’s Zepbound Leads Weight Loss With 50 Pounds Lost; FDA Raises Concerns, California Proposes Medi-Cal Cuts

30 days ago

Eli Lilly’s Tirzepatide Leads to 50-Pound Loss in 72-Week Trial, Outperforms Semaglutide Amid Medi-Cal Coverage Cuts

1 month ago

Zepbound (Tirzepatide) Outperforms Wegovy (Semaglutide) in 72-Week Weight Loss Trial, Achieving 50 Pounds Loss

1 month ago

Lilly’s Zepbound Cuts Weight 20% in 72-Week Trial, Beating Novo Nordisk’s Wegovy

1 month ago

Eli Lilly's Zepbound Surpasses Novo Nordisk's Wegovy in SURMOUNT-5 Trial, Achieving 20.2% vs 13.7% Weight Loss; CVS Health Drops Zepbound

1 month ago

Eli Lilly's Zepbound Achieves 20.2% Weight Loss, Outperforming Novo Nordisk's Wegovy in SURMOUNT-5 Trial

1 month ago•Original version

Eli Lilly's Zepbound Achieves 20.2% Weight Loss vs. 13.7% for Novo Nordisk's Wegovy in 72-Week SURMOUNT-5 Trial

Sources

A newer version of this article is available. Read the latest version

Listen to this article

Economics

Pharma

Business

Listen to this article

Eli Lilly's Zepbound Surpasses Novo Nordisk's Wegovy in SURMOUNT-5 Trial, Achieving 20.2% vs 13.7% Weight Loss; CVS Health Drops Zepbound

70 posts • Grok (2)

Updated May 12, 2025, 04:19 PM

Eli Lilly & Co.'s obesity drug Zepbound, also known as tirzepatide or Mounjaro, has demonstrated superior weight loss results compared to Novo Nordisk A/S's Wegovy, or semaglutide, in the SURMOUNT-5 head-to-head trial. The study, published in the New England Journal of Medicine and presented at the European Congress on Obesity, involved 751 participants across the US. Patients on Zepbound lost an average of 20.2% of their body weight, or 50.3 pounds, compared to 13.7% or 33.1 pounds for those on Wegovy over 72 weeks.

The trial also highlighted Zepbound's effectiveness in achieving key secondary endpoints, including greater reductions in waist circumference and improvements in weight reduction targets. Participants taking Zepbound experienced an average waist reduction of 18.4 centimeters, compared to 13 centimeters for those on Wegovy. Both drugs were associated with primarily gastrointestinal-related adverse events, which were generally mild to moderate. Rates of nausea were similar at around 44%, diarrhea at about 23%, but Zepbound had a lower rate of vomiting at 15% compared to 21% with Wegovy. Discontinuation rates due to these events were lower with Zepbound at 6.1% compared to 8.0% with Wegovy.

Despite Zepbound's superior performance in the trial, CVS Health Corp.'s Caremark has decided to drop Zepbound from its coverage, compelling patients to switch to Wegovy. This decision comes amidst a backdrop of market dynamics where Eli Lilly has been gaining ground in obesity prescriptions, increasing its market share to 62% from 56%, while Wegovy's market share fell to 38% from 43%. Novo Nordisk faces challenges, including a significant drop in its stock value following comments from US President Donald Trump on drug pricing.

More breaking stories on DeepNewz — updated live.

Eli Lilly and Company

@EliLillyandCo

New today: the full results of a study comparing our obesity medicine to another therapy were published in the @NEJM and presented at the European Congress on Obesity. Read more: https://t.co/8MxDZmNxgS https://t.co/LhOJYMhJpX

Eric Topol

@EricTopol

Just published @NEJM A randomized trial of Semaglutide (Ozempic) vs Tirzepatide (Mounjaro, Zepbound) at max doses demonstrates superiority of the latter for weight loss https://t.co/udkldBm8gA https://t.co/VtXNSrEgMo

Toronto Sun

@TheTorontoSun

Lilly’s Zepbound trims more belly fat than Novo’s Wegovy: Study https://t.co/mTHiFou6vN https://t.co/vB7Po1WiXB

The Independent

@Independent

IN FOCUS | The first head-to-head trial of obesity drugs reveals a clear winner for effective weight loss. But how does it work, and what are the long-term effects? Anna Magee reports https://t.co/PBwqP37iy5

BBC News Brasil

@bbcbrasil

First comparative test of two successful weight-loss drugs showed that Mounjaro (tirzepatide), from the drugmaker Eli Lilly, is more effective than its competitor Wegovy (semaglutide, the same active ingredient as Ozempic), from Novo Nordisk: https://t.co/vth30BgiTV https://t.co/rTGclMqoK9

#Zepbound #Mounjaro #Wegovy #European Congress on Obesity #US #Caremark #Eli Lilly #Novo Nordisk #Donald Trump

Related Prediction Markets

Sources

Story Timeline

Similar Stories

Sources